JAGUAR HEALTH, INC. Operating Expenses
JAGUAR HEALTH, INC. (JAGX) reported Operating Expenses of $7.36 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2019-05-21
- JAGUAR HEALTH, INC. operating expenses for the quarter ending 2019-03-31 was $7.36M, a 24.14% increase year-over-year.
- JAGUAR HEALTH, INC. operating expenses for the quarter ending 2018-12-31 was $13.71M, a 38.32% decline year-over-year.
- JAGUAR HEALTH, INC. operating expenses for the quarter ending 2018-09-30 was $7.64M, a 9.50% decline year-over-year.
- JAGUAR HEALTH, INC. operating expenses for the quarter ending 2018-06-30 was $7.96M, a 145.26% increase year-over-year.
- JAGUAR HEALTH, INC. operating expenses for fiscal 2018 was $35.24M, a 8.72% decline from fiscal 2017.
- JAGUAR HEALTH, INC. operating expenses for fiscal 2017 was $38.61M, a 181.25% increase from fiscal 2016.
- JAGUAR HEALTH, INC. operating expenses for fiscal 2016 was $13.73M, a 8.06% increase from fiscal 2015.
- JAGUAR HEALTH, INC. operating expenses for fiscal 2015 was $12.70M, a 52.77% increase from fiscal 2014.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2019-03-31 | $7.36M 10-Q · filed 2019-05-21 | $21.07M derived: sum of 2 quarters · filed 2019-05-21 | $28.71M derived: sum of 3 quarters · filed 2019-05-21 | $36.67M derived: sum of 4 quarters · filed 2019-05-21 |
| 2018-12-31 | $13.71M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | $21.34M derived: sum of 2 quarters · filed 2019-04-10 | $29.31M derived: sum of 3 quarters · filed 2019-04-10 | $35.24M 10-K · filed 2019-04-10 |
| 2018-09-30 | $7.64M 10-Q · filed 2018-11-19 | $15.60M derived: sum of 2 quarters · filed 2018-11-19 | $21.53M 10-Q · filed 2018-11-19 | $43.76M derived: sum of 4 quarters · filed 2019-05-21 |
| 2018-06-30 | $7.96M 10-Q · filed 2018-08-13 | $13.90M 10-Q · filed 2018-08-13 | $36.12M derived: sum of 3 quarters · filed 2019-05-21 | $44.56M derived: sum of 4 quarters · filed 2019-05-21 |
| 2018-03-31 | $5.93M 10-Q · filed 2019-05-21 | $28.16M derived: sum of 2 quarters · filed 2019-05-21 | $36.60M derived: sum of 3 quarters · filed 2019-05-21 | $39.84M derived: sum of 4 quarters · filed 2019-05-21 |
| 2017-12-31 | $22.22M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | $30.66M derived: sum of 2 quarters · filed 2019-04-10 | $33.91M derived: sum of 3 quarters · filed 2019-04-10 | $38.61M 10-K · filed 2019-04-10 |
| 2017-09-30 | $8.44M 10-Q · filed 2018-11-19 | $11.69M derived: sum of 2 quarters · filed 2018-11-19 | $16.39M 10-Q · filed 2018-11-19 | $19.73M derived: sum of 4 quarters · filed 2018-11-19 |
| 2017-06-30 | $3.25M 10-Q · filed 2018-08-13 | $7.94M 10-Q · filed 2018-08-13 | $11.29M derived: sum of 3 quarters · filed 2018-08-13 | $14.52M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-03-31 | $4.70M 10-Q · filed 2018-05-15 | $8.04M derived: sum of 2 quarters · filed 2018-05-15 | $11.27M derived: sum of 3 quarters · filed 2018-05-15 | $14.70M derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | $6.57M derived: sum of 2 quarters · filed 2018-04-09 | $10.00M derived: sum of 3 quarters · filed 2018-04-09 | $13.73M 10-K · filed 2018-04-09 |
| 2016-09-30 | $3.23M 10-Q · filed 2017-11-20 | $6.66M derived: sum of 2 quarters · filed 2017-11-20 | $10.38M 10-Q · filed 2017-11-20 | $14.28M derived: sum of 4 quarters · filed 2017-11-20 |
| 2016-06-30 | $3.43M 10-Q · filed 2017-08-09 | $7.16M 10-Q · filed 2017-08-09 | $11.05M derived: sum of 3 quarters · filed 2017-08-09 | $13.89M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | $3.72M 10-Q/A · filed 2017-06-23 | $7.62M derived: sum of 2 quarters · filed 2017-06-23 | $10.45M derived: sum of 3 quarters · filed 2017-06-23 | $13.69M derived: sum of 4 quarters · filed 2017-06-23 |
| 2015-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $6.73M derived: sum of 2 quarters · filed 2017-02-15 | $9.96M derived: sum of 3 quarters · filed 2017-02-15 | $12.70M 10-K · filed 2017-02-15 |
| 2015-09-30 | $2.83M 10-Q · filed 2016-11-14 | $6.06M derived: sum of 2 quarters · filed 2016-11-14 | $8.81M 10-Q · filed 2016-11-14 | $10.65M derived: sum of 4 quarters · filed 2016-11-14 |
| 2015-06-30 | $3.23M 10-Q · filed 2016-08-15 | $5.97M 10-Q · filed 2016-08-15 | $7.82M derived: sum of 3 quarters · filed 2016-08-15 | $10.40M derived: sum of 4 quarters · filed 2016-08-15 |
| 2015-03-31 | $2.74M 10-Q · filed 2016-05-10 | $4.58M derived: sum of 2 quarters · filed 2016-05-10 | $7.17M derived: sum of 3 quarters · filed 2016-05-10 | $9.10M derived: sum of 4 quarters · filed 2016-05-10 |
| 2014-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | $4.43M derived: sum of 2 quarters · filed 2016-03-29 | $6.36M derived: sum of 3 quarters · filed 2016-03-29 | $8.32M 10-K · filed 2016-03-29 |
| 2014-09-30 | $2.58M 10-Q · filed 2015-11-13 | $4.52M derived: sum of 2 quarters · filed 2015-11-13 | $6.47M 10-Q · filed 2015-11-13 | |
| 2014-06-30 | $1.94M 10-Q · filed 2015-08-13 | $3.89M 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | $1.95M 10-Q · filed 2015-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |